UBS O'Connor’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $803K | Buy |
14,523
+1,183
| +9% | +$65.4K | 0.04% | 226 |
|
|
2025
Q1 | $645K | Buy |
+13,340
| New | +$645K | 0.02% | 199 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 474 |
|
|
2024
Q3 | – | Sell |
-68,231
| Closed | -$2.36M | – | 505 |
|
|
2024
Q2 | $2.36M | Sell |
68,231
-41,099
| -38% | -$1.42M | 0.07% | 171 |
|
|
2024
Q1 | $3.16M | Buy |
109,330
+3,176
| +3% | +$91.9K | 0.09% | 120 |
|
|
2023
Q4 | $2.43M | Sell |
106,154
-30,114
| -22% | -$691K | 0.08% | 147 |
|
|
2023
Q3 | $2.27M | Buy |
136,268
+69,174
| +103% | +$1.15M | 0.04% | 222 |
|
|
2023
Q2 | $1.85M | Sell |
67,094
-41,379
| -38% | -$1.14M | 0.04% | 308 |
|
|
2023
Q1 | $2.49M | Buy |
+108,473
| New | +$2.49M | 0.06% | 234 |
|
|
2022
Q4 | – | Sell |
-232,820
| Closed | -$1.96M | – | 242 |
|
|
2022
Q3 | $1.96M | Buy |
232,820
+13,000
| +6% | +$110K | 0.02% | 622 |
|
|
2022
Q2 | $1.74M | Buy |
+219,820
| New | +$1.74M | 0.02% | 676 |
|